Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

T HEMANTH RAO

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1023070745
CMS profile
677428
Location
CHARLOTTE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$0.83

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Education $0.83 1

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
Travere Therapeutics, Inc. $0.83 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

T HEMANTH RAO

NPI 1023070745 · CMS profile ID 677428

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

CHARLOTTE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1023070745?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
T HEMANTH RAO, NPI 1023070745, CMS profile ID 677428. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1023070745?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). T HEMANTH RAO, NPI 1023070745, CMS profile ID 677428. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1023070745?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
T HEMANTH RAO, NPI 1023070745, CMS profile ID 677428, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1023070745?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $0.83 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Travere Therapeutics, Inc. $0.8301/02/2022 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 960079589 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $5.57 2
PY2022 $0.83 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2022
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2022
Generated from
OP_DTL_GNRL_PGYR2022_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $590,566.02 42
PY2024 Principal investigator $757,803.02 58
PY2023 Principal investigator $705,507.39 95
PY2022 Recipient $3,120.00 1
PY2022 Principal investigator $783,014.66 39
PY2021 Principal investigator $424,194.70 79
PY2020 Principal investigator $514,521.07 71
PY2019 Principal investigator $249,052.37 33

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

58 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 GENZYME CORPORATION $16,176.00 12/09/2024 Non-covered Recipient Entity
The Neurological Instit,PA
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1128715405
Principal investigator 1 SANOFI US SERVICES INC. $7,251.60 12/03/2024 Non-covered Recipient Entity
The Neurological Instit,PA
A Phase 2, Double-blind, Randomized, Placebo-controlled Study Assessing Efficacy and Safety of SAR441344, a CD40L-antagonist Monoclonal Antibody, in Participants With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1128715403
Principal investigator 1 Janssen Research & Development, LLC $5,932.00 12/02/2024 Non-covered Recipient Entity
The Neurological Inst Pa
80202135CDP3001 No dispute reported 06/30/2026 1078969671
Principal investigator 1 SANOFI US SERVICES INC. $10,667.40 11/12/2024 Non-covered Recipient Entity
The Neurological Instit,PA
A Phase 2, Double-blind, Randomized, Placebo-controlled Study Assessing Efficacy and Safety of SAR441344, a CD40L-antagonist Monoclonal Antibody, in Participants With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1128715401
Principal investigator 1 SANOFI US SERVICES INC. $16,167.20 10/21/2024 Non-covered Recipient Entity
The Neurological Instit,PA
A Phase 2, Double-blind, Randomized, Placebo-controlled Study Assessing Efficacy and Safety of SAR441344, a CD40L-antagonist Monoclonal Antibody, in Participants With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1128715399
Principal investigator 1 F. Hoffmann-La Roche AG $258.00 10/16/2024 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1133454622
Principal investigator 1 F. Hoffmann-La Roche AG $2,821.00 10/16/2024 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1133454626
Principal investigator 1 F. Hoffmann-La Roche AG $258.00 10/16/2024 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1133454630
Principal investigator 1 Janssen Research & Development, LLC $6,942.00 10/09/2024 Non-covered Recipient Entity
The Neurological Inst Pa
80202135CDP3001 No dispute reported 06/30/2026 1078969755
Principal investigator 1 SANOFI US SERVICES INC. $19,898.00 10/02/2024 Non-covered Recipient Entity
The Neurological Instit,PA
A Phase 2, Double-blind, Randomized, Placebo-controlled Study Assessing Efficacy and Safety of SAR441344, a CD40L-antagonist Monoclonal Antibody, in Participants With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1128715397
Principal investigator 1 F. Hoffmann-La Roche AG $2,821.00 09/18/2024 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1133454618
Principal investigator 1 Janssen Research & Development, LLC $12,587.00 09/06/2024 Non-covered Recipient Entity
The Neurological Inst Pa
80202135CDP3001 No dispute reported 06/30/2026 1078969795
Principal investigator 1 F. Hoffmann-La Roche AG $2,821.00 08/27/2024 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1133454607
Principal investigator 1 Janssen Research & Development, LLC $7,892.00 08/21/2024 Non-covered Recipient Entity
The Neurological Inst Pa
80202135CDP3001 No dispute reported 06/30/2026 1078969799
Principal investigator 1 F. Hoffmann-La Roche AG $2,821.00 07/17/2024 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1133454611
Principal investigator 1 F. Hoffmann-La Roche AG $7,548.00 07/17/2024 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1133454615
Principal investigator 1 SANOFI US SERVICES INC. $1,712.70 07/15/2024 Non-covered Recipient Entity
The Neurological Instit,PA
A Phase 2, Double-blind, Randomized, Placebo-controlled Study Assessing Efficacy and Safety of SAR441344, a CD40L-antagonist Monoclonal Antibody, in Participants With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1128715395
Principal investigator 1 Janssen Research & Development, LLC $3,640.00 06/27/2024 Non-covered Recipient Entity
The Neurological Inst Pa
80202135CDP3001 No dispute reported 06/30/2026 1078969815
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $4,400.00 06/18/2024 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF AVP-786 (DEUTERATED [D6]-DEXTROMETHORPHAN HYDROBROMIDE [D6-DM]/QUINIDINE SULFATE [Q]) FOR THE TREATMENT OF AGITATION IN PATIENTS WITH DEMENTIA OF THE ALZHEIMERS TYPE No dispute reported 06/30/2026 1118846028
Principal investigator 1 SANOFI US SERVICES INC. $12,755.70 06/10/2024 Non-covered Recipient Entity
The Neurological Instit,PA
A Phase 2, Double-blind, Randomized, Placebo-controlled Study Assessing Efficacy and Safety of SAR441344, a CD40L-antagonist Monoclonal Antibody, in Participants With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1128715393
Principal investigator 1 Hoffmann-La Roche Limited $3,088.80 06/04/2024 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
Satralizumab open label treatment study in patients with NMOSD No dispute reported 06/30/2026 1133454547
Principal investigator 1 Hoffmann-La Roche Limited $2,844.00 06/04/2024 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
Satralizumab open label treatment study in patients with NMOSD No dispute reported 06/30/2026 1133454551
Principal investigator 1 Janssen Research & Development, LLC $5,561.00 05/27/2024 Non-covered Recipient Entity
The Neurological Inst Pa
80202135CDP3001 No dispute reported 06/30/2026 1078969813
Principal investigator 1 Hoffmann-La Roche Limited $927.00 05/23/2024 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
Satralizumab open label treatment study in patients with NMOSD No dispute reported 06/30/2026 1133454544
Principal investigator 1 F. Hoffmann-La Roche AG $7,548.00 05/17/2024 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1133454591
Principal investigator 1 F. Hoffmann-La Roche AG $258.00 05/17/2024 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1133454603
Principal investigator 1 Janssen Research & Development, LLC $30,944.00 05/17/2024 Non-covered Recipient Entity
The Neurological Inst Pa
80202135CDP3001 No dispute reported 06/30/2026 1078969783
Principal investigator 1 Roche Products Limited $1,119.00 05/16/2024 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
A randomized, placebo and active-controlled dose finding study to evaluate the efficacy, as measured by brain MRI lesions, and safety of 2 dose regimens of ocrelizumab in patients with relapsing-remitting multiple sclerosis No dispute reported 06/30/2026 1133454634
Principal investigator 1 Roche Products Limited $1,119.00 05/16/2024 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
A randomized, placebo and active-controlled dose finding study to evaluate the efficacy, as measured by brain MRI lesions, and safety of 2 dose regimens of ocrelizumab in patients with relapsing-remitting multiple sclerosis No dispute reported 06/30/2026 1133454638
Principal investigator 1 Roche Products Limited $1,563.00 05/16/2024 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
A randomized, placebo and active-controlled dose finding study to evaluate the efficacy, as measured by brain MRI lesions, and safety of 2 dose regimens of ocrelizumab in patients with relapsing-remitting multiple sclerosis No dispute reported 06/30/2026 1133454642
Principal investigator 1 Roche Products Limited $1,563.00 05/16/2024 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
A randomized, placebo and active-controlled dose finding study to evaluate the efficacy, as measured by brain MRI lesions, and safety of 2 dose regimens of ocrelizumab in patients with relapsing-remitting multiple sclerosis No dispute reported 06/30/2026 1133454646
Principal investigator 1 Roche Products Limited $1,563.00 05/16/2024 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
A randomized, placebo and active-controlled dose finding study to evaluate the efficacy, as measured by brain MRI lesions, and safety of 2 dose regimens of ocrelizumab in patients with relapsing-remitting multiple sclerosis No dispute reported 06/30/2026 1133454650
Principal investigator 1 Roche Products Limited $1,119.00 05/16/2024 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
A randomized, placebo and active-controlled dose finding study to evaluate the efficacy, as measured by brain MRI lesions, and safety of 2 dose regimens of ocrelizumab in patients with relapsing-remitting multiple sclerosis No dispute reported 06/30/2026 1133454654
Principal investigator 1 Hoffmann-La Roche Limited $1,852.00 05/07/2024 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
Satralizumab open label treatment study in patients with NMOSD No dispute reported 06/30/2026 1133454539
Principal investigator 1 Janssen Research & Development, LLC $2,251.00 05/06/2024 Non-covered Recipient Entity
The Neurological Inst Pa
80202135CDP3001 No dispute reported 06/30/2026 1078969859
Principal investigator 1 F. Hoffmann-La Roche AG $258.00 04/17/2024 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1133454571
Principal investigator 1 F. Hoffmann-La Roche AG $258.00 04/17/2024 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1133454575
Principal investigator 1 F. Hoffmann-La Roche AG $7,548.00 04/17/2024 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1133454583
Principal investigator 1 F. Hoffmann-La Roche AG $258.00 04/17/2024 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1133454595
Principal investigator 1 F. Hoffmann-La Roche AG $258.00 04/17/2024 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1133454599
Principal investigator 1 Hoffmann-La Roche Limited $3,708.00 04/16/2024 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
Satralizumab open label treatment study in patients with NMOSD No dispute reported 06/30/2026 1133454555
Principal investigator 1 F. Hoffmann-La Roche AG $258.00 04/01/2024 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1133454579
Principal investigator 1 F. Hoffmann-La Roche AG $7,548.00 04/01/2024 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1133454587
Principal investigator 1 Hoffmann-La Roche Limited $1,935.90 03/26/2024 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
Satralizumab open label treatment study in patients with NMOSD No dispute reported 06/30/2026 1133454531
Principal investigator 1 SANOFI US SERVICES INC. $4,948.20 03/18/2024 Non-covered Recipient Entity
The Neurological Instit,PA
A Phase 2, Double-blind, Randomized, Placebo-controlled Study Assessing Efficacy and Safety of SAR441344, a CD40L-antagonist Monoclonal Antibody, in Participants With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1128715391
Principal investigator 1 Hoffmann-La Roche Limited $633.60 03/05/2024 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
Satralizumab open label treatment study in patients with NMOSD No dispute reported 06/30/2026 1133454535
Principal investigator 1 F. Hoffmann-La Roche AG $2,821.00 02/16/2024 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1133454567
Principal investigator 1 SANOFI US SERVICES INC. $8,255.60 02/05/2024 Non-covered Recipient Entity
The Neurological Instit,PA
A Phase 2, Double-blind, Randomized, Placebo-controlled Study Assessing Efficacy and Safety of SAR441344, a CD40L-antagonist Monoclonal Antibody, in Participants With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1128715389
Principal investigator 1 Novartis Pharmaceuticals Corporation $13,589.60 01/31/2024 Non-covered Recipient Entity
NEUROLOGICAL INSTITUTE PA
An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1089696709
Principal investigator 1 Novartis Pharmaceuticals Corporation $36,606.00 01/30/2024 Non-covered Recipient Entity
NEUROLOGICAL INSTITUTE PA
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1089696675
Principal investigator 1 F. Hoffmann-La Roche AG $258.00 01/24/2024 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1133454559
Principal investigator 1 F. Hoffmann-La Roche AG $7,548.00 01/24/2024 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1133454563
Principal investigator 1 Janssen Research & Development, LLC $60,277.00 01/23/2024 Non-covered Recipient Entity
The Neurological Inst Pa
80202135CDP3001 No dispute reported 06/30/2026 1078969825
Principal investigator 1 SANOFI US SERVICES INC. $7,761.00 01/22/2024 Non-covered Recipient Entity
The Neurological Instit,PA
A Phase 2, Double-blind, Randomized, Placebo-controlled Study Assessing Efficacy and Safety of SAR441344, a CD40L-antagonist Monoclonal Antibody, in Participants With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1128715387
Principal investigator 1 Hoffmann-La Roche Limited $1,935.90 01/18/2024 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
Satralizumab open label treatment study in patients with NMOSD No dispute reported 06/30/2026 1133454527
Principal investigator 1 Novartis Pharmaceuticals Corporation $24,394.85 01/09/2024 Non-covered Recipient Entity
NEUROLOGICAL INSTITUTE
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1089685419
Principal investigator 1 SANOFI US SERVICES INC. $31,055.70 01/03/2024 Non-covered Recipient Entity
The Neurological Instit,PA
A Phase 2, Double-blind, Randomized, Placebo-controlled Study Assessing Efficacy and Safety of SAR441344, a CD40L-antagonist Monoclonal Antibody, in Participants With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1128715385
Principal investigator 1 Novartis Pharmaceuticals Corporation $326,999.27 01/01/2024 Non-covered Recipient Entity
NEUROLOGICAL INSTITUTE
An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1089685777